Loading...
Please wait, while we are loading the content...
Eficacia de maraviroc en los ensayos clínicos de desarrollo de la molécula
| Content Provider | Semantic Scholar |
|---|---|
| Author | Moreno, Santiago Hernández, Beatríz Gutierrez, Carolina Delsol, Enrique |
| Copyright Year | 2008 |
| Abstract | compared studies, were carried out on patients infected by HIV-1 with R5 tropism and resistant to drugs from three families of retrovirals. Maraviroc two times per day achieved < 50 copies/mL in 45.5% of the patients compared to 16.7% in the placebo group (p < 0.001). The CD4+ lymphocyte count had a mean of 63 cells/mm 3 higher with Maraviroc. The drug was shown to be superior in all patient groups regardless of the baseline viral load, the baseline CD4+ lymphocyte count or the number of accompanying active drugs. In the study on patients infected by HIV with X4/dual/mixed tropism, Maraviroc, was not virologically effective, but did produce a CD4 increase higher than the placebo. Maraviroc was compared with Efavirenz in the study on patients with no previous treatment and with R5-tropic virus. At 48 weeks, the percentage of patients with a viral load of <50 copies/mL was 69.3% in the group that received Efavirenz and 65.3% in the Maraviroc group. In conclusion, Maraviroc has demonstrated its increased efficacy in patients with CCR5-tropic virus and a long history of antiretroviral use and failure, and in patients with no previous treatment. |
| Starting Page | 17 |
| Ending Page | 22 |
| Page Count | 6 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/S0213-005X(08)76559-5 |
| Volume Number | 26 |
| Alternate Webpage(s) | https://www.elsevier.es/index.php?p=revista&pRevista=pdf-simple&pii=S0213005X08765595 |
| Alternate Webpage(s) | https://doi.org/10.1016/S0213-005X%2808%2976559-5 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
